Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Change in Cash (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Change in Cash for 15 consecutive years, with -$952807.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash fell 24.91% year-over-year to -$952807.0, compared with a TTM value of -$887000.0 through Sep 2025, up 9.91%, and an annual FY2024 reading of -$336487.0, up 59.43% over the prior year.
  • Change in Cash was -$952807.0 for Q3 2025 at BioRestorative Therapies, down from $326462.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $19.9 million in Q4 2021 and bottomed at -$11.4 million in Q3 2022.
  • Average Change in Cash over 5 years is -$129587.7, with a median of -$629364.0 recorded in 2021.
  • The sharpest move saw Change in Cash plummeted 18190.53% in 2021, then skyrocketed 2173.28% in 2024.
  • Year by year, Change in Cash stood at $19.9 million in 2021, then crashed by 124.42% to -$4.9 million in 2022, then surged by 67.29% to -$1.6 million in 2023, then soared by 40.77% to -$941554.0 in 2024, then decreased by 1.2% to -$952807.0 in 2025.
  • Business Quant data shows Change in Cash for BRTX at -$952807.0 in Q3 2025, $326462.0 in Q2 2025, and $680899.0 in Q1 2025.